Loading stock data...

Pfizer Limited

NSE: PFIZER BSE: PFIZER

NSE
5,289.00 -2.00 (-0.04%)

Prev Close

5291

Open Price

5300

Volume

15,517

Today Low / High

5251.5 / 5320

52 WK Low / High

3701 / 6451.15

Range

5,025 - 5,553

BSE
5,289.55 -1.35 (-0.03%)

Prev Close

5290.9

Open Price

5250.05

Volume

594

Today Low / High

5250.05 / 5320

52 WK Low / High

3742.9 / 6452.85

Range

5,025 - 5,554

The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 5289 (target range: 5,025 - 5,553), reflecting a change of -2 (-0.03780004%). On the BSE, it is listed at 5289.55 (target range: 5,025 - 5,554), showing a change of -1.35 (-0.02551551%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.

23 Jul 5,322.00 -0.58%
22 Jul 5,342.00 -0.91%
21 Jul 5,349.50 -0.28%
18 Jul 5,371.00 -0.96%
17 Jul 5,365.50 -0.07%
16 Jul 5,415.00 -1.16%
15 Jul 5,448.00 -0.31%
14 Jul 5,509.00 -1.78%
11 Jul 5,443.00 1.36%
10 Jul 5,613.00 -2.48%
09 Jul 5,685.50 -0.29%
08 Jul 5,874.00 -0.39%
07 Jul 5,820.00 0.27%
04 Jul 5,800.00 -0.28%
03 Jul 5,730.00 0.92%
02 Jul 5,690.00 0.44%
01 Jul 5,749.00 -0.88%
30 Jun 5,750.00 -1.26%
27 Jun 5,681.00 0.30%

Pfizer Limited Graph

Pfizer Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Pfizer Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 5,289.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 5,289.55 5,342.45 4,808.20 - 5,876.69
5,395.34 4,316.27 - 6,474.41
5,448.24 3,813.77 - 7,082.71
Bearish Scenario 5,289.55 5,236.65 4,712.99 - 5,760.32
5,183.76 4,147.01 - 6,220.51
5,130.86 3,591.60 - 6,670.12

Overview of Pfizer Limited

ISIN

INE182A01018

Industry

Drug Manufacturers - General

Vol.Avg

61,391

Market Cap

265,553,173,600

Last Dividend

35

Official Website

Visit Website

IPO Date

2002-07-01

DCF Diff

-89.14

DCF

5,381

Financial Ratios Every Investor Needs

Stock Dividend of PFIZER

Date Label Adj Dividend Dividend Record Date Payment Date Declaration Date
2025-07-09 July 09, 25 35 35 2025-07-09 2025-08-20
2024-08-21 August 21, 24 35 35 2024-08-21 2024-09-06
2023-08-11 August 11, 23 35 35 2023-08-11 2023-09-16
2022-09-19 September 19, 22 30 30 2022-09-20 2022-09-30
2022-08-18 August 18, 22 35 35 2022-08-19 2022-09-23

Stock Rating Details for PFIZER

Metric Value Recommendation
Overall Rating A- Buy
DCF Score 4 Buy
ROE Score 5 Strong Buy
ROA Score 5 Strong Buy
Debt-to-Equity (DE) Score 3 Neutral
Price-to-Earnings (PE) Score 2 Sell
Price-to-Book (PB) Score 2 Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 2,281.35 Cr 810.45 Cr 1,470.90 Cr 0.6447 0.00 Cr 0.00 Cr 1,099.57 Cr 767.60 Cr 167.79 740.23 Cr 0.3365
2024-03-31 2,192.69 Cr 795.23 Cr 1,397.46 Cr 0.6373 0.00 Cr 103.80 Cr 577.06 Cr 551.33 Cr 120.51 823.78 Cr 0.2514
2023-03-31 2,424.76 Cr 873.67 Cr 1,551.09 Cr 0.6397 0.00 Cr 264.66 Cr 804.40 Cr 623.93 Cr 136.38 941.51 Cr 0.2573
2022-03-31 2,610.55 Cr 948.03 Cr 1,662.52 Cr 0.6368 0.00 Cr 129.15 Cr 778.53 Cr 612.56 Cr 133.89 897.20 Cr 0.2346
2021-03-31 2,238.43 Cr 797.74 Cr 1,440.69 Cr 0.6436 0.00 Cr 97.29 Cr 678.36 Cr 497.61 Cr 108.77 792.13 Cr 0.2223

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 2,800.98 Cr 4,911.11 Cr 693.70 Cr 4,217.4100 Cr 108.40 Cr -2,692.58 Cr 475.92 Cr 179.46 Cr 0.00 Cr 0.00 Cr 0.00 Cr 569.5100 Cr
2024-03-31 112.00 Cr 4,228.78 Cr 633.24 Cr 3,595.5400 Cr 94.54 Cr -17.46 Cr 433.69 Cr 151.52 Cr 56.63 Cr 0.00 Cr -1,900.32 Cr 546.5600 Cr
2023-03-31 36.60 Cr 4,000.73 Cr 793.43 Cr 3,207.3000 Cr 134.47 Cr 97.87 Cr 417.70 Cr 185.46 Cr 3.48 Cr 0.00 Cr 0.00 Cr 657.3500 Cr
2022-03-31 62.76 Cr 3,900.51 Cr 1,036.10 Cr 2,864.4100 Cr 166.99 Cr 104.23 Cr 448.90 Cr 220.07 Cr 1.43 Cr -10.25 Cr 7.48 Cr 852.8900 Cr
2021-03-31 157.03 Cr 3,265.90 Cr 872.86 Cr 2,393.0400 Cr 105.91 Cr -51.12 Cr 435.05 Cr 195.14 Cr 202.63 Cr 0.00 Cr 434.48 Cr 774.3400 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 659.7500 Cr -71.3400 Cr -205.3400 Cr 631.6000 Cr 383.0700 Cr 495.0700 Cr -28.1500 Cr 767.6000 Cr -37.3100 Cr -160.2500 Cr -42.2200 Cr
2024-03-31 256.8400 Cr -75.1300 Cr -235.1400 Cr 237.9100 Cr 75.4000 Cr 112.0000 Cr -18.9300 Cr 551.3300 Cr 0.0000 Cr -183.4300 Cr -16.0000 Cr
2023-03-31 355.6800 Cr -36.0500 Cr -345.7900 Cr 290.7000 Cr -26.1600 Cr 36.6000 Cr -64.9800 Cr 824.0100 Cr -35.2000 Cr -297.2100 Cr 21.8500 Cr
2022-03-31 667.0800 Cr -575.0200 Cr -180.5100 Cr 651.7700 Cr -88.4500 Cr 62.7600 Cr -15.3100 Cr 772.8900 Cr -9.8900 Cr -159.7400 Cr -13.8600 Cr
2021-03-31 427.3300 Cr -468.8400 Cr -1,571.0700 Cr 409.6300 Cr -1,612.5800 Cr 151.2100 Cr -17.7000 Cr 668.7200 Cr -49.0900 Cr -1,519.3500 Cr -4.4600 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-03-31 591.91 Cr 202.48 Cr 389.43 Cr 0.6579 306.52 Cr 330.94 Cr 72.34 226.30 Cr 0.5591
2024-12-31 537.99 Cr 196.56 Cr 341.43 Cr 0.6346 131.19 Cr 127.60 Cr 27.89 188.75 Cr 0.2372
2024-09-30 588.59 Cr 326.47 Cr 262.12 Cr 0.4453 174.26 Cr 158.35 Cr 34.61 232.32 Cr 0.2690
2024-06-30 562.86 Cr 306.66 Cr 256.20 Cr 0.4552 162.89 Cr 150.71 Cr 32.94 177.49 Cr 0.2678
2024-03-31 546.63 Cr 278.20 Cr 268.43 Cr 0.4911 175.68 Cr 178.86 Cr 39.10 264.56 Cr 0.3272

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-03-31 2,800.98 Cr 0.00 Cr 2,800.98 Cr 193.09 Cr 475.92 Cr 3,512.85 Cr 179.46 Cr 4,911.11 Cr 693.70 Cr
2024-12-31 0.00 Cr 0.00 Cr 2,281.32 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -3,750.87 Cr
2024-09-30 35.34 Cr 2,245.98 Cr 2,281.32 Cr 227.51 Cr 454.82 Cr 3,022.73 Cr 135.27 Cr 4,458.60 Cr 707.73 Cr
2024-06-30 -2,046.71 Cr 4,093.42 Cr 2,046.71 Cr 0.00 Cr 0.00 Cr 2,046.71 Cr 0.00 Cr 0.00 Cr -3,595.54 Cr
2024-03-31 2,046.71 Cr 1,947.73 Cr 2,046.71 Cr 187.61 Cr 433.69 Cr 2,737.81 Cr 151.35 Cr 4,228.78 Cr 633.24 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2025-03-31 330.94 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-12-31 127.60 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 158.35 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 150.71 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-03-31 178.86 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Splits History

Date Label Split Ratio
2000-06-12 June 12, 00 2:1

Similar Stocks: Drug Manufacturers - General

Company Name Symbol Price Market Cap Volume
Cipla Limited CIPLA ₹1,487.90 ₹1,201,852,712,900.00 ₹1,389,115.00
Abbott India Limited ABBOTINDIA ₹34,580.00 ₹734,800,794,000.00 ₹6,926.00
GlaxoSmithKline Pharmaceuticals Limited GLAXO ₹3,162.40 ₹535,729,534,400.00 ₹68,919.00
Gland Pharma Limited GLAND ₹2,018.10 ₹332,494,083,600.00 ₹191,604.00
Pfizer Limited PFIZER ₹5,289.00 ₹241,959,585,300.00 ₹15,517.00
Sanofi India Limited SANOFI ₹5,922.50 ₹136,395,175,000.00 ₹7,407.00
Marksans Pharma Limited MARKSANS ₹231.60 ₹104,952,782,400.00 ₹2,226,046.00

Key Executives

India Digital Client Partner Lead
Mr. Chaitanya Nadkarni

Gender: male

Year Born:

Senior Director of Policy & Public Affairs
Mr. Sharad Goswami

Gender: male

Year Born:

Whole-Time Director & Executive Director of Plant Operations
Mr. Pazhania Pillai Rengan

Gender: male

Year Born: 1978

Senior Director of Business Operations
Mr. Anil Pattanshetty

Gender: male

Year Born:

Director of Corporate Services, Company Secretary & Compliance Officer
Mr. Prajeet Nair C.S.

Gender: male

Year Born:

Category Lead of Internal Medicine
Mr. Prashant Mahalingam

Gender: male

Year Born:

MD & Chief Executive Officer
Ms. Meenakshi Nevatia

Gender: female

Year Born: 1970

Director of People Experience
Ms. Shilpi Singh

Gender: female

Year Born:

Strategic Partnerships, Channel Development & International Neighbouring Markets Lead
Mr. Deepak Rakheja

Gender: male

Year Born:

FAQs about Pfizer Limited

Who is the CEO of the company?

The CEO is Meenakshi Nevatia.

What is the current market price of the stock?

The current price is ₹5,291.00.

What is the 52-week price range?

The range is ₹3701-6451.15.

What is the market capitalization of the company?

The market capitalization is ₹26,555.32 crores.

What is the dividend yield?

The dividend yield is 6.72%.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 18.25.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Pfizer Limited (ISIN: INE182A01018) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹26,555.32 crores and an average daily volume of 61,391 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹35.

Welcome to the Investing and Trading Information platform: InvesTrack.in

Note: This platform is for educational and informational purposes only. Do not consider anything as financial advice.

QUICK LINKS

Home
About us
Contact us
Privacy Policy
Disclaimer
Sitemap
Investing
Trading
Top Brokers
Tools
Live Analysis

STAY CONNECTED

Follow Us On Social Media
Get Latest Update On Social Media
Facebook Instagram Twitter

General Disclaimer: InvesTrack is an educational platform and not any type of investment advisory platform. Our Blog and videos are based on countless hours of research and experience, which you can use as a guide for your research purposes. None of our content should be considered a piece of investment advice. Earning Disclosure: InvesTrack is a community supported platform. We may earn a commission when you make a purchase through one of our links at no extra cost to you. Note: We are not SEBI Registered Advisors. This website is purely for training and educational purposes. We shall not be responsible for your profit or loss.

© Copyright 2024 - 2025 | InvesTrack